Microvascular damage in systemic sclerosis: Detection and monitoring with biomarkers

被引：10
作者：
Hummers L.K. [1 ]
机构：
[1] Johns Hopkins SSc Center, Baltimore, MD 21224
来源：
Current Rheumatology Reports | 2006年 / 8卷 / 2期
关键词：
Pulmonary Arterial Hypertension; Hepatocyte Growth Factor; Interstitial Lung Disease; Rheumatol; Scleroderma;
D O I：
10.1007/s11926-006-0053-z
中图分类号：
学科分类号：
摘要：
Vascular disease is universal in patients with systemic sclerosis (SSc), but there is a wide variability in its severity. It is clear that there is an early insult to the microvasculature, followed-up by on-going chronic process. This results in profound vascular damage in a subset of patients who develop severe events such as digital loss and pulmonary arterial hypertension. Although there is abundant evidence of vascular perturbation from studies of peripheral blood in SSc, there are few data about the ability to use these biomarkers to predict vascular outcomes. This paper examines the possibility of using circulating biomarkers to assess vascular disease activity and to predict severe vascular events among patients with SSc. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：131 / 137
页数：6
相关论文
共 55 条
[1]  
Ungerer R.G., Tashkin D.P., Furst D., Et al., Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis, Am J Med, 75, pp. 65-74, (1983)
[2]  
Ter Borg E.J., Piersma-Wichers G., Smit A.J., Et al., Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma, Semin Arthritis Rheum, 24, pp. 40-47, (1994)
[3]  
Ohtsuka T., Hasegawa A., Nakano A., Et al., Nailfold capillary abnormality and pulmonary hypertension in systemic sclerosis, Int J Dermatol, 36, pp. 116-122, (1997)
[4]  
Ong Y.Y., Nikoloutsopoulos T., Bond C.P., Et al., Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension, Asian Pac J Allergy Immunol, 16, pp. 81-86, (1998)
[5]  
Steen V., Medsger Jr. T.A., Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement, Arthritis Rheum, 48, pp. 516-522, (2003)
[6]  
Medsger Jr. T.A., Assessment of damage and activity in systemic sclerosis, Curr Opin Rheumatol, 12, pp. 545-548, (2000)
[7]  
Medsger Jr. T.A., Silman A.J., Steen V.D., Et al., A disease severity scale for systemic sclerosis: Development and testing, J Rheumatol, 26, pp. 2159-2167, (1999)
[8]  
Clements P.J., Wong W.K., Hurwitz E.L., Et al., The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial, Arthritis Rheum, 44, pp. 653-661, (2001)
[9]  
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clin Pharmacol Ther, 69, pp. 89-95, (2001)
[10]  
Kahaleh M.B., Vascular involvement in systemic sclerosis (SSc), Clin Exp Rheumatol 2004, 22, SUPPL. 33
123456